Trademark: 87003192
Status Date
Tuesday, January 23, 2018
Registration Number
5383250
Registration Date
Tuesday, January 23, 2018
Filing Date
Friday, April 15, 2016
Published for Opposition
Tuesday, November 7, 2017
41 Co-sponsoring and providing educational conferences, both live and via telephone conferences, seminars, classes and workshops in the field of cancer-related issues and distribution of educational materials in connection therewith; on-line journals, namely, blogs featuring information in the field of cancer-related issues; providing podcasts and non-downloadable videos in the field of cancer-related issues; providing on-line journals, namely, blogs featuring cancer-related issues and postings in honor of patients and in memory of patients
36 Charitable fundraising to support providing educational services and information about prevention, screening, diagnosis and treatment of cancer, cancer patient navigation services, cancer patient and clinical trials advocacy programs, research, development and regulatory approval of methods, drugs and devices for prevention, screening, diagnosis and treatment of cancer, lobbying and legislation regarding cancer-related issues, patient-provider communications, and patient-payor communications; providing information concerning the patient's financial reimbursement from medical insurers and patient assistance programs in the nature of cost-mitigating health reimbursement arrangements for cancer treatment; providing information regarding insurance coverage and patient assistance programs in the nature of cost-mitigating health reimbursement arrangements for cancer patients for diagnostic tests, drugs and medical devices
35 Lobbying services, namely, promoting the interests of cancer patients, cancer researchers, cancer treatment providers, and others involved with cancer research, diagnosis and treatment; providing information in the field of patient-payor communications in which information regarding medical billing can be exchanged; providing information in the field of government affairs related to the expanded access to experimental cancer drugs for compassionate use; providing physician and medical specialist referrals to patients fighting chronic diseases and lethal diseases for assisting in the access to second opinions; providing information in the nature of discounts and rebates for cancer patients for diagnostic tests, drugs and medical devices
45 Providing patient advocacy and patient advocate services in the field of cancer treatment; providing cancer patient advocacy programs; providing advocacy services to potential participants and participants in clinical trials; providing information in the field of personal emotional support of cancer patients and patients' families; providing information in the field of regulatory affairs compliance relating to the approval of anticancer compounds in the U.S. and abroad
44 Providing information about prevention, screening, diagnosis and treatment of cancer; providing a website, and links to the websites of others, featuring information about prevention, screening, diagnosis and treatment of cancer; providing information in the field of patient medical information where patients can inquire about medical issues and be directed to resources for medical information customized to their need for information about their condition; providing information in the field of cancer prevention, screening, diagnosis and treatment; providing information in the field of cancer treatment for the benefit of patients and patients' families; providing information in the field of communications between patients and health care providers in which patient medical information can be exchanged; providing information in the field of patient access to diagnostic tests, drugs and medical devices provided by health care facilities; providing information in the field of medicine, personalized medicine, pathology, oncology, interventional radiology, radiogenomics, and anesthesiology; providing information in the field of complementary and alternative medicine for use in the prevention and treatment of cancer; providing access to medical specialists for second opinions for patients fighting chronic diseases and lethal diseases
42 Providing information in the field of anti-cancer drug discovery and development; providing information in the field of clinical trials
Jan 12, 2024
Teas Section 8 & 15 Received
Jan 23, 2023
Courtesy Reminder - Sec. 8 (6-Yr) E-Mailed
Jan 23, 2018
Registered-Principal Register
Nov 7, 2017
Official Gazette Publication Confirmation E-Mailed
Nov 7, 2017
Published For Opposition
Oct 18, 2017
Notification Of Notice Of Publication E-Mailed
Oct 1, 2017
Assigned To Lie
Sep 16, 2017
Approved For Pub - Principal Register
Sep 8, 2017
Teas/Email Correspondence Entered
Sep 7, 2017
Correspondence Received In Law Office
Sep 7, 2017
Teas Request For Reconsideration Received
Mar 19, 2017
Notification Of Final Refusal Emailed
Mar 19, 2017
Final Refusal E-Mailed
Mar 19, 2017
Final Refusal Written
Feb 3, 2017
Teas/Email Correspondence Entered
Feb 2, 2017
Correspondence Received In Law Office
Feb 2, 2017
Teas Response To Office Action Received
Aug 3, 2016
Notification Of Non-Final Action E-Mailed
Aug 3, 2016
Non-Final Action E-Mailed
Aug 3, 2016
Non-Final Action Written
Jul 29, 2016
Assigned To Examiner
Apr 21, 2016
Notice Of Pseudo Mark E-Mailed
Apr 20, 2016
New Application Office Supplied Data Entered
Apr 19, 2016
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
